Patent Assignment
Reel/Frame 036515/0084
Security Interest
Recorded: 2015-08-31
Pages: 15
Assignor
KADMON CORPORATION, LLC
Executed: 2015-08-28
Assignee
PERCEPTIVE CREDIT OPPORTUNITIES FUND, LP
499 PARK AVENUE, 25TH FLOOR, C/O PERCEPTIVE ADVISORS LLC, NEW YORK, NEW YORK, 10022
Covered Properties
(52)
Rho Kinase Inhibitors
PCT:
PCT/US2014/059572 ↗
Immunomodulatory Agents
PCT:
PCT/US2015/011657 ↗
Treatment of Brain and Central Nervous System Tumors
PCT:
PCT/US2015/019658 ↗
Treatment of Gvhd
PCT:
PCT/US2015/025176 ↗
Farnesyl Derivatives and Pharmaceutical Compositions Containing Them
Patent:
5,705,528 →
Application:
08/338,764 →
Non-Malignant Disease Treatment with Ras Antagonists
Patent:
6,462,086 →
Application:
09/597,332 →
Herbal Composition PHY906 and Its Use in Chemotheraphy
Treatment of Post-Angioplasty Restenosis and Atherosclerosis with Ras Antagonists
Receptor-Type Kinase Modulators and Methods of Use
Farnesyl Derivatives and Pharmaceutical Compositions Containing Them
Patent:
39,682 →
Application:
11/093,255 →
Herbal Composition PHY906 and Its Use in Chemotherapy
Inhibitors of Microsomal Triglyceride Transfer Protein and Apo-B Secretion
Antibodies That Bind Mmp-14
Methods and Compositions for Oral Delivery of Fts
Pharmacokinetically Improved Compounds
Treatment of Viral Infections by Modulation of Host Cell Metabolic Pathways
Compositions and Methods for Treating Osteolytic Disorders Comprising Mmp-14 Binding Proteins
Evaluating Mmp Expression in Patient Stratification and Other Therapeutic, Diagnostic and Prognostic Methods for Cancer
Receptor-Type Kinase Modulators and Methods of Use
Treatment of Lung Cancer
Herbal Composition PHY906 and Its Use in Chemotherapy
Alkoxyalkyl S-Prenylthiosalicylates for Treatment of Cancer
Metalloproteinase Binding Proteins
Use of the Combination of PHY906 and a Tyrosine Kinase Inhibitor as a Cancer Treatment Regimen
Rho Kinase Inhibitors
Application:
13/255,879 →
Publication:
US 2012/0202793
Method for Treating Breast Cancer Using Antibody Binding to Mmp-14
Compositions and Methods for Treating Osteolytic Disorders Comprising Mmp-14 Binding Proteins
Inhibitors of Mtor Kinase as Anti-Viral Agents
Application:
13/386,547 →
Publication:
US 2012/0190676
Treatment of Viral Infections by Modulation of Host Cell Metabolic Pathways
Treatment of Multiple Sclerosis
Application:
13/521,637 →
Publication:
US 2013/0035390
Inhibitors of Long and Very Long Chain Fatty Acid Metabolism as Broad Spectrum Anti-Virals
Pharmacokinetically Improved Compounds
Pharmacokinetically Improved Compounds
Use of a Receptor-Type Kinase Modulator for Treating Polycystic Kidney Disease
Inhibitors of Mtor Kinase as Anti -Viral Agent
Application:
13/982,331 →
Publication:
US 2014/0206678
Processes for the Preparation of Substituted Quinazolines
Combination Therapy Comprising an Mmp-14 Binding Protein
Rho Kinase Inhibitors
Treatment of Ocular Disorders
Application:
14/431,948 →
Publication:
US 2015/0238601
Human Anti-Vegfr-2/Kdr Antibodies
Herbal Composition PHY906 and Its Use in Chemotherapy
Rho-Kinase Inhibitors and Method of Preparation
Use of PHY906 as Treatment for Inflammatory Bowel Disease and/or Irritable Bowel Syndrome
Inhibitors of Microsomal Triglyceride Transfer Protein and Apo-B Secretion
Methods and Compositions for Oral Delivery of Fts
Application:
14/662,420 →
Publication:
US 2015/0191426
Treatment of Viral Infections by Modulation of Host Cell Metabolic Pathways
Application:
14/709,756 →
Methods for Treatment of Breast Cancer Nonresponsive to Trastuzumab
Human Anti-Vegfr-2/Kdr Antibodies
Application:
62/061,097 →
Stable Trientine Formulations
Application:
62/111,522 →
Anti-PD1 Antibodies
Application:
62/113,132 →
Glucose Uptake Inhibitors
Application:
62/185,223 →
Treatment of Infectious Diseases with Glucose Uptake Inhibitors
Application:
62/185,231 →
Related Assignments
(16)
Other recorded transfers of the patents in this record — the chain of ownership.
Confirmatory License
May 4, 2012
From: PRINCETON UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 028156/0742 →
Security Agreement
Feb 7, 2013
From: KADMON CORPORATION, LLC
To: CORTLAND CAPITAL MARKET SERVICES LLC
Reel/Frame 029777/0502 →
Security Agreement
Jun 25, 2013
From: KADMON CORPORATION LLC
To: MACQUARIE US TRADING LLC
Reel/Frame 030679/0116 →
Security Agreement
Jun 25, 2013
From: KADMON CORPORATION LLC
To: MACQUARIE US TRADING LLC
Reel/Frame 030679/0212 →
Assignment of Assignor's Interest
Jan 6, 2015
From: KIM, JI-IN; LIU, KEVIN; POYUROVSKY, MASHA; LU, DAN
To: KADMON CORPORATION, LLC
Reel/Frame 034647/0005 →
Release of Security Interest
Sep 1, 2015
From: MACQUARIE US TRADING LLC
To: KADMON CORPORATION, LLC
Reel/Frame 036518/0862 →
Security Interest
Sep 8, 2015
From: KADMON CORPORATION, LLC
To: MACQUARIE US TRADING LLC
Reel/Frame 036573/0001 →
Nunc Pro Tunc Assignment
Jul 15, 2016
From: CONCORDIA PHARMACEUTICALS, INC.
To: KADMON CORPORATION, LLC
Reel/Frame 039166/0591 →
Assignment of Assignor's Interest
Jul 22, 2016
From: KADMON CORPORATION, LLC
To: RAMOT AT TEL-AVIV UNIVERSITY LTD.
Reel/Frame 039225/0943 →
Corrective Assignment to Correct the Assignor's Name Previously Recorded at Reel: 039166 Frame: 0591. Assignor(S) Hereby Confirms the Assignment.
Aug 16, 2016
From: CONCORDIA PHARMACEUTICALS, LLC
To: KADMON CORPORATION, LLC
Reel/Frame 040314/0329 →
Termination of Patent and Trademark Security Agreement
Nov 25, 2019
From: PERCEPTIVE CREDIT OPPORTUNITIES FUND, LP
To: KADMON CORPORATION, LLC
Reel/Frame 051106/0677 →
Assignment of Assignor's Interest
May 18, 2021
From: DYAX CORP.
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 056268/0983 →
Merger and Change of Name
Sep 10, 2021
From: SURFACE LOGIX, INC.; SURFACE LOGIX, LLC
To: SURFACE LOGIX, LLC
Reel/Frame 057468/0052 →
Release of Security Interest
Oct 21, 2021
From: CORTLAND CAPITAL MARKET SERVICES LLC
To: KADMON CORPORATION, LLC
Reel/Frame 057886/0192 →
Release of Security Interest
Oct 29, 2021
From: MACQUARIE US TRADING LLC
To: KADMON CORPORATION, LLC
Reel/Frame 057973/0751 →
Entity Conversion
Sep 17, 2025
From: SURFACE LOGIX, INC.
To: SURFACE LOGIX LLC
Reel/Frame 072915/0828 →